source
- PepGen soars on promising early data for muscular dystrophy drugWhile from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.BioPharma Dive · 9d ago↗ source
- Oura to buy AI care startup Counsel Health for $625MWearable ringmaker Oura is buying AI primary care startup Counsel Health. Oura is paying $625 million in cash for Counsel, which offers medical AI services as well as virtual visits with doctors. T…Endpoints · 9d ago↗ source
- Recon: Bayer wins FDA approval for stroke prevention drug; Third Rock enters $2B partnership with AI-focused Chinese biotechWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 10d ago